Large-scale cohort studies with patient-level clinical data including CD4 count and use of HAART have the potential to better inform the management of melanoma risk (amongst other cancers) in populations with HIV/AIDS by better understanding the impact of immunosuppression, as well as how known risk factors operate differently in these populations versus the general population. This evidence concerns the gene CD4 and cancer.